Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed st...
Momenta Pharmaceuticals is a biotechnology comp...
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...
CollPlant is a regenerative medicine company fo...
Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets ultrasoni...
Misonix, Inc. (Nasdaq: MSON) designs, develops,...
TransMedics is a commercial-stage medical technology company transforming organ tr...
TransMedics is a commercial-stage medical techn...
We are a vertically integrated, clinical stage gene therapy company with four ongo...
We are a vertically integrated, clinical stage ...
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncol...
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) ...
Founded in 1998, GW is a biopharmaceutical company focused on discovering, develop...
Founded in 1998, GW is a biopharmaceutical comp...
Join the National Investor Network and get the latest information with your interests in mind.